1 Al-Hajj, M, Wicha, MS, Benito-Hernandez, A et al. 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983–3988.

1 Al-Hajj, M, Wicha, MS, Benito-Hernandez, A et al. 2003Prospective identification of tumorigenic breast cancer cellsProc Natl Acad Sci USA1003983–3988.)| false
• Search Google Scholar
• Export Citation

2 Andre, F, Hatzis, C, Anderson, K et al. 2007 Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer Clin Cancer Res 13 2061–2067.

2 Andre, F, Hatzis, C, Anderson, K et al. 2007Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancerClin Cancer Res132061–2067.)| false
• Search Google Scholar
• Export Citation

3 Ayers, M, Symmans, WF, Stec, J et al. 2004 Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2284–2293.

3 Ayers, M, Symmans, WF, Stec, J et al. 2004Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancerJ Clin Oncol222284–2293.)| false
• Search Google Scholar
• Export Citation

4 Bardou, VJ, Arpino, G, Elledge, RM et al. 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 1973–1979.

4 Bardou, VJ, Arpino, G, Elledge, RM et al. 2003Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databasesJ Clin Oncol211973–1979.)| false
• Search Google Scholar
• Export Citation

5 Bast, RC, Jr, Hortobagyi, GN 2004 Individualized care for patients with cancer – a work in progress N Engl J Med 351 2865–2867.

5 Bast, RC, Jr, Hortobagyi, GN2004Individualized care for patients with cancer – a work in progressN Engl J Med3512865–2867.)| false
• Search Google Scholar
• Export Citation

6 Berry, DA, Cirrincione, C, Henderson, IC et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 1658–1667.

6 Berry, DA, Cirrincione, C, Henderson, IC et al. 2006Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA2951658–1667.)| false
• Search Google Scholar
• Export Citation

7 Bhat, KM, Setaluri, V 2007 Microtubule-associated proteins as targets in cancer chemotherapy Clin Cancer Res 13 2849–2854.

7 Bhat, KM, Setaluri, V2007Microtubule-associated proteins as targets in cancer chemotherapyClin Cancer Res132849–2854.)| false
• Search Google Scholar
• Export Citation

8 Bieche, I, Lidereau, R 1995 Genetic alterations in breast cancer Genes Chromosomes Cancer 14 227–251.

8 Bieche, I, Lidereau, R1995Genetic alterations in breast cancerGenes Chromosomes Cancer14227–251.)| false
• Search Google Scholar
• Export Citation

9 Blumencranz, P, Whitworth, PW, Deck, K et al. 2007 Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors Am J Surg 194 426–432.

9 Blumencranz, P, Whitworth, PW, Deck, K et al. 2007Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errorsAm J Surg194426–432.)| false
• Search Google Scholar
• Export Citation

10 Broyde, A, Boycov, O, Strenov, Y et al. 2009 Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma Am J Hematol 84 338–343.

10 Broyde, A, Boycov, O, Strenov, Y et al. 2009Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphomaAm J Hematol84338–343.)| false
• Search Google Scholar
• Export Citation

11 Bueno-de-Mesquita, JM, Linn, SC, Keijzer, R et al. 2009 Validation of 70-gene prognosis signature in node-negative breast cancer Breast Cancer Res Treat 117 483–495.

11 Bueno-de-Mesquita, JM, Linn, SC, Keijzer, R et al. 2009Validation of 70-gene prognosis signature in node-negative breast cancerBreast Cancer Res Treat117483–495.)| false
• Search Google Scholar
• Export Citation

12 Carter, P, Presta, L, Gorman, CM et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285–4289.

12 Carter, P, Presta, L, Gorman, CM et al. 1992Humanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci USA894285–4289.)| false
• Search Google Scholar
• Export Citation

13 Chang, HY, Nuyten, DS, Sneddon, JB et al. 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci USA 102 3738–3743.

13 Chang, HY, Nuyten, DS, Sneddon, JB et al. 2005Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survivalProc Natl Acad Sci USA1023738–3743.)| false
• Search Google Scholar
• Export Citation

14 Chang, HY, Sneddon, JB, Alizadeh, AA et al. 2004 Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds PLoS Biol 2 E7.

14 Chang, HY, Sneddon, JB, Alizadeh, AA et al. 2004Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and woundsPLoS Biol2E7.)| false
• Search Google Scholar
• Export Citation

15 Cheang, MC, Voduc, D, Bajdik, C et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368–1376.

15 Cheang, MC, Voduc, D, Bajdik, C et al. 2008Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeClin Cancer Res141368–1376.)| false
• Search Google Scholar
• Export Citation

16 Davis, LM, Harris, C, Tang, L et al. 2007 Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma J Mol Diagn 9 327–336.

16 Davis, LM, Harris, C, Tang, L et al. 2007Amplification patterns of three genomic regions predict distant recurrence in breast carcinomaJ Mol Diagn9327–336.)| false
• Search Google Scholar
• Export Citation

17 Debatin, KM, Krammer, PH 2004 Death receptors in chemotherapy and cancer Oncogene 23 2950–2966.

17 Debatin, KM, Krammer, PH2004Death receptors in chemotherapy and cancerOncogene232950–2966.)| false
• Search Google Scholar
• Export Citation

18 Drach, J, Gattringer, C, Glassl, H et al. 1992 The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma Hematol Oncol 10 125–134.

18 Drach, J, Gattringer, C, Glassl, H et al. 1992The biological and clinical significance of the Ki-67 growth fraction in multiple myelomaHematol Oncol10125–134.)| false
• Search Google Scholar
• Export Citation

19 Duffy, MJ 2005 Predictive markers in breast and other cancers: a review Clin Chem 51 494–503.

19 Duffy, MJ 2005 Predictive markers in breast and other cancers: a review Clin Chem 51 494–503.)| false
• Search Google Scholar
• Export Citation

20 Duffy, MJ, McCarthy, K 1998 Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review) Int J Oncol 12 1343–1348.

20 Duffy, MJ, McCarthy, K1998Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review)Int J Oncol121343–1348.)| false
• Search Google Scholar
• Export Citation

21 Dvorak, HF 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1650–1659.

21 Dvorak, HF 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1650–1659.)| false
• Search Google Scholar
• Export Citation

22 Fan, C, Oh, DS, Wessels, L et al. 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 560–569.

22 Fan, C, Oh, DS, Wessels, L et al. 2006Concordance among gene-expression-based predictors for breast cancerN Engl J Med355560–569.)| false
• Search Google Scholar
• Export Citation

23 Fodor, SP, Rava, RP, Huang, XC et al. 1993 Multiplexed biochemical assays with biological chips Nature 364 555–556.

23 Fodor, SP, Rava, RP, Huang, XC et al. 1993Multiplexed biochemical assays with biological chipsNature364555–556.)| false
• Search Google Scholar
• Export Citation

24 Gennari, A, Sormani, MP, Pronzato, P et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14–20.

24 Gennari, A, Sormani, MP, Pronzato, P et al. 2008HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsJ Natl Cancer Inst10014–20.)| false
• Search Google Scholar
• Export Citation

25 Gerdes, J, Schwab, U, Lemke, H et al. 1983 Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 13–20.

25 Gerdes, J, Schwab, U, Lemke, H et al. 1983Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer3113–20.)| false
• Search Google Scholar
• Export Citation

26 Glas, AM, Floore, A, Delahaye, LJ et al. 2006 Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 278.

26 Glas, AM, Floore, A, Delahaye, LJ et al. 2006Converting a breast cancer microarray signature into a high-throughput diagnostic testBMC Genomics7278.)| false
• Search Google Scholar
• Export Citation

27 Goetz, MP, Suman, VJ, Ingle, JN et al. 2006 A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen Clin Cancer Res 12 2080–2087.

27 Goetz, MP, Suman, VJ, Ingle, JN et al. 2006A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifenClin Cancer Res122080–2087.)| false
• Search Google Scholar
• Export Citation

28 Goldhirsch, A, Coates, AS, Gelber, RD et al. 2006 First--select the target: better choice of adjuvant treatments for breast cancer patients Ann Oncol 17 1772–1776.

28 Goldhirsch, A, Coates, AS, Gelber, RD et al. 2006First--select the target: better choice of adjuvant treatments for breast cancer patientsAnn Oncol171772–1776.)| false
• Search Google Scholar
• Export Citation

29 Gong, Y, Yan, K, Lin, F et al. 2007 Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study Lancet Oncol 8 203–211.

29 Gong, Y, Yan, K, Lin, F et al. 2007Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyLancet Oncol8203–211.)| false
• Search Google Scholar
• Export Citation

30 Gralow, JR, Burstein, HJ, Wood, W et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814–819.

30 Gralow, JR, Burstein, HJ, Wood, W et al. 2008Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable diseaseJ Clin Oncol26814–819.)| false
• Search Google Scholar
• Export Citation

31 Gyorffy, B, Gyorffy, A, Tulassay, Z 2005 A “multiple testing” problémája és a genomiális kísérletekre alkalmazott megoldások Orvosi Hetilap 146 559–563.

31 Gyorffy, B, Gyorffy, A, Tulassay, Z2005A “multiple testing” problémája és a genomiális kísérletekre alkalmazott megoldásokOrvosi Hetilap146559–563.)| false
• Search Google Scholar
• Export Citation

32 Habel, LA, Shak, S, Jacobs, MK et al. 2006 A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 R25.

32 Habel, LA, Shak, S, Jacobs, MK et al. 2006A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patientsBreast Cancer Res8R25.)| false
• Search Google Scholar
• Export Citation

33 Harris, L, Fritsche, H, Mennel, R et al. 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287–5312.

33 Harris, L, Fritsche, H, Mennel, R et al. 2007American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol255287–5312.)| false
• Search Google Scholar
• Export Citation

34 Harvey, JM, Clark, GM, Osborne, CK et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474–1481.

34 Harvey, JM, Clark, GM, Osborne, CK et al. 1999Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancerJ Clin Oncol171474–1481.)| false
• Search Google Scholar
• Export Citation

35 Hu, Z, Fan, C, Oh, DS et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96.

35 Hu, Z, Fan, C, Oh, DS et al. 2006The molecular portraits of breast tumors are conserved across microarray platformsBMC Genomics796.)| false
• Search Google Scholar
• Export Citation

36 Iverson, AA, Gillett, C, Cane, P et al. 2009 A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens J Mol Diagn 11 117–130.

36 Iverson, AA, Gillett, C, Cane, P et al. 2009A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimensJ Mol Diagn11117–130.)| false
• Search Google Scholar
• Export Citation

37 Iyer, VR, Eisen, MB, Ross, DT et al. 1999 The transcriptional program in the response of human fibroblasts to serum Science 283 83–87.

37 Iyer, VR, Eisen, MB, Ross, DT et al. 1999The transcriptional program in the response of human fibroblasts to serumScience28383–87.)| false
• Search Google Scholar
• Export Citation

38 Janicke, F, Prechtl, A, Thomssen, C et al. 2001 Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst 93 913–920.

38 Janicke, F, Prechtl, A, Thomssen, C et al. 2001Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1J Natl Cancer Inst93913–920.)| false
• Search Google Scholar
• Export Citation

39 Jansen, MP, Sieuwerts, AM, Look, MP et al. 2007 HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study J Clin Oncol 25 662–668.

39 Jansen, MP, Sieuwerts, AM, Look, MP et al. 2007HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective studyJ Clin Oncol25662–668.)| false
• Search Google Scholar
• Export Citation

40 Jerevall, PL, Brommesson, S, Strand, C et al. 2008 Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome Breast Cancer Res Treat 107 225–234.

40 Jerevall, PL, Brommesson, S, Strand, C et al. 2008Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcomeBreast Cancer Res Treat107225–234.)| false
• Search Google Scholar
• Export Citation

41 Kakarala, M, Wicha, MS 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 2813–2820.

41 Kakarala, M, Wicha, MS2008Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapyJ Clin Oncol262813–2820.)| false
• Search Google Scholar
• Export Citation

42 Liu, R, Wang, X, Chen, GY et al. 2007 The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 217–226.

42 Liu, R, Wang, X, Chen, GY et al. 2007The prognostic role of a gene signature from tumorigenic breast-cancer cellsN Engl J Med356217–226.)| false
• Search Google Scholar
• Export Citation

43 Loi, S, Haibe-Kains, B, Desmedt, C et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade J Clin Oncol 25 1239–1246.

43 Loi, S, Haibe-Kains, B, Desmedt, C et al. 2007Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic gradeJ Clin Oncol251239–1246.)| false
• Search Google Scholar
• Export Citation

44 Look, MP, Putten van, WL, Duffy, MJ et al. 2002 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 116–128.

44 Look, MP, Putten van, WL, Duffy, MJ et al. 2002Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patientsJ Natl Cancer Inst94116–128.)| false
• Search Google Scholar
• Export Citation

45 Ma, XJ, Hilsenbeck, SG, Wang, W et al. 2006 The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer J Clin Oncol 24 4611–4619.

45 Ma, XJ, Hilsenbeck, SG, Wang, W et al. 2006The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerJ Clin Oncol244611–4619.)| false
• Search Google Scholar
• Export Citation

46 Ma, XJ, Salunga, R, Dahiya, S et al. 2008 A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer Clin Cancer Res 14 2601–2608.

46 Ma, XJ, Salunga, R, Dahiya, S et al. 2008A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancerClin Cancer Res142601–2608.)| false
• Search Google Scholar
• Export Citation

47 Ma, XJ, Wang, Z, Ryan, PD et al. 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 607–616.

47 Ma, XJ, Wang, Z, Ryan, PD et al. 2004A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell5607–616.)| false
• Search Google Scholar
• Export Citation

48 Mano, MS, Rosa, DD, De, AE et al. 2007 The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours Cancer Treat Rev 33 64–77.

48 Mano, MS, Rosa, DD, De, AE et al. 2007The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumoursCancer Treat Rev3364–77.)| false
• Search Google Scholar
• Export Citation

49 Mansel, RE, Goyal, A, Douglas-Jones, A et al. 2009 Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room: results of the Cardiff study Breast Cancer Res Treat 115 595–600.

49 Mansel, RE, Goyal, A, Douglas-Jones, A et al. 2009Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room: results of the Cardiff studyBreast Cancer Res Treat115595–600.)| false
• Search Google Scholar
• Export Citation

50 Miyabe, S, Okabe, M, Nagatsuka, H et al. 2009 Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases J Oral Maxillofac Surg 67 1432–1441.

50 Miyabe, S, Okabe, M, Nagatsuka, H et al. 2009Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 casesJ Oral Maxillofac Surg671432–1441.)| false
• Search Google Scholar
• Export Citation

51 Molina, R, Barak, V, Dalen van, A et al. 2005 Tumor markers in breast cancer – European Group on Tumor Markers recommendations Tumour Biol 26 281–293.

51 Molina, R, Barak, V, Dalen van, A et al. 2005Tumor markers in breast cancer – European Group on Tumor Markers recommendationsTumour Biol26281–293.)| false
• Search Google Scholar
• Export Citation

52 Mook, S, Bonnefoi, H, Pruneri, G et al. 2009 Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial Eur J Cancer 45 1201–1208.

52 Mook, S, Bonnefoi, H, Pruneri, G et al. 2009Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trialEur J Cancer451201–1208.)| false
• Search Google Scholar
• Export Citation

53 Mook, S, Schmidt, MK, Viale, G et al. 2009 The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 116 295–302.

53 Mook, S, Schmidt, MK, Viale, G et al. 2009The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation studyBreast Cancer Res Treat116295–302.)| false
• Search Google Scholar
• Export Citation

54 Nielsen, TO, Hsu, FD, Jensen, K et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367–5374.

54 Nielsen, TO, Hsu, FD, Jensen, K et al. 2004Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaClin Cancer Res105367–5374.)| false
• Search Google Scholar
• Export Citation

55 Onitilo, AA, Engel, JM, Greenlee, RT et al. 2009 Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 4–13.

55 Onitilo, AA, Engel, JM, Greenlee, RT et al. 2009Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survivalClin Med Res74–13.)| false
• Search Google Scholar
• Export Citation

56 Paik, S, Shak, S, Tang, G et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817–2826.

56 Paik, S, Shak, S, Tang, G et al. 2004A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med3512817–2826.)| false
• Search Google Scholar
• Export Citation

57 Paik, S, Tang, G, Shak, S et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726–3734.

57 Paik, S, Tang, G, Shak, S et al. 2006Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol243726–3734.)| false
• Search Google Scholar
• Export Citation

58 Parker, JS, Mullins, M, Cheang, MC et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160–1167.

58 Parker, JS, Mullins, M, Cheang, MC et al. 2009Supervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol271160–1167.)| false
• Search Google Scholar
• Export Citation

59 Peintinger, F, Anderson, K, Mazouni, C et al. 2007 Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer Clin Cancer Res 13 4078–4082.

59 Peintinger, F, Anderson, K, Mazouni, C et al. 2007Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancerClin Cancer Res134078–4082.)| false
• Search Google Scholar
• Export Citation

60 Perou, CM, Sorlie, T, Eisen, MB et al. 2000 Molecular portraits of human breast tumours Nature 406 747–752.

60 Perou, CM, Sorlie, T, Eisen, MB et al. 2000Molecular portraits of human breast tumoursNature406747–752.)| false
• Search Google Scholar
• Export Citation

61 Ponti, D, Costa, A, Zaffaroni, N et al. 2005 Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res 65 5506–5511.

61 Ponti, D, Costa, A, Zaffaroni, N et al. 2005Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell propertiesCancer Res655506–5511.)| false
• Search Google Scholar
• Export Citation

62 Pritchard, KI 2009 Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol 27 3875–3876.

62 Pritchard, KI 2009 Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol 27 3875–3876.)| false
• Search Google Scholar
• Export Citation

63 Rhodes, A, Jasani, B, Barnes, DM et al. 2000 Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems J Clin Pathol 53 125–130.

63 Rhodes, A, Jasani, B, Barnes, DM et al. 2000Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systemsJ Clin Pathol53125–130.)| false
• Search Google Scholar
• Export Citation

64 Ring, BZ, Seitz, RS, Beck, R et al. 2006 Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer J Clin Oncol 24 3039–3047.

64 Ring, BZ, Seitz, RS, Beck, R et al. 2006Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerJ Clin Oncol243039–3047.)| false
• Search Google Scholar
• Export Citation

65 Ross, DT, Kim, CY, Tang, G et al. 2008 Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials Clin Cancer Res 14 6602–6609.

65 Ross, DT, Kim, CY, Tang, G et al. 2008Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trialsClin Cancer Res146602–6609.)| false
• Search Google Scholar
• Export Citation

66 Ross, JS, Hatzis, C, Symmans, WF et al. 2008 Commercialized multigene predictors of clinical outcome for breast cancer Oncologist 13 477–493.

66 Ross, JS, Hatzis, C, Symmans, WF et al. 2008Commercialized multigene predictors of clinical outcome for breast cancerOncologist13477–493.)| false
• Search Google Scholar
• Export Citation

67 Ross, JS, Symmans, WF, Pusztai, L et al. 2007 Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes Clin Cancer Res 13 2831–2835.

67 Ross, JS, Symmans, WF, Pusztai, L et al. 2007Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodesClin Cancer Res132831–2835.)| false
• Search Google Scholar
• Export Citation

68 Rouzier, R, Rajan, R, Wagner, P et al. 2005 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer Proc Natl Acad Sci USA 102 8315–8320.

68 Rouzier, R, Rajan, R, Wagner, P et al. 2005Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerProc Natl Acad Sci USA1028315–8320.)| false
• Search Google Scholar
• Export Citation

69 Shi, L, Reid, LH, Jones, WD et al. 2006 The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 1151–1161.

69 Shi, L, Reid, LH, Jones, WD et al. 2006The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNat Biotechnol241151–1161.)| false
• Search Google Scholar
• Export Citation

70 Shipitsin, M, Campbell, LL, Argani, P et al. 2007 Molecular definition of breast tumor heterogeneity Cancer Cell 11 259–273.

70 Shipitsin, M, Campbell, LL, Argani, P et al. 2007Molecular definition of breast tumor heterogeneityCancer Cell11259–273.)| false
• Search Google Scholar
• Export Citation

71 Simon, JA, Szankasi, P, Nguyen, DK et al. 2000 Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae Cancer Res 60 328–333.

71 Simon, JA, Szankasi, P, Nguyen, DK et al. 2000Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiaeCancer Res60328–333.)| false
• Search Google Scholar
• Export Citation

72 Sorlie, T, Perou, CM, Tibshirani, R et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869–10874.

72 Sorlie, T, Perou, CM, Tibshirani, R et al. 2001Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci USA9810869–10874.)| false
• Search Google Scholar
• Export Citation

73 Sotiriou, C, Neo, SY, McShane, LM et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 10393–10398.

73 Sotiriou, C, Neo, SY, McShane, LM et al. 2003Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProc Natl Acad Sci USA10010393–10398.)| false
• Search Google Scholar
• Export Citation

74 Sotiriou, C, Wirapati, P, Loi, S et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262–272.

74 Sotiriou, C, Wirapati, P, Loi, S et al. 2006Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosisJ Natl Cancer Inst98262–272.)| false
• Search Google Scholar
• Export Citation

75 Steeg, PS, Zhou, Q 1998 Cyclins and breast cancer Breast Cancer Res Treat 52 17–28.

75 Steeg, PS, Zhou, Q1998Cyclins and breast cancerBreast Cancer Res Treat5217–28.)| false
• Search Google Scholar
• Export Citation

76 Straver, ME, Glas, AM, Hannemann, J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009.

76 Straver, ME, Glas, AM, Hannemann, J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat2009.)| false
• Search Google Scholar
• Export Citation

77 Surowiak, P, Matkowski, R, Materna, V et al. 2005 Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance Histol Histopathol 20 1037–1044.

77 Surowiak, P, Matkowski, R, Materna, V et al. 2005Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistanceHistol Histopathol201037–1044.)| false
• Search Google Scholar
• Export Citation

78 Symmans, WF, Peintinger, F, Hatzis, C et al. 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414–4422.

78 Symmans, WF, Peintinger, F, Hatzis, C et al. 2007Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapyJ Clin Oncol254414–4422.)| false
• Search Google Scholar
• Export Citation

79 Tanner, M, Isola, J, Wiklund, T et al. 2006 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 2428–2436.

79 Tanner, M, Isola, J, Wiklund, T et al. 2006Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401J Clin Oncol242428–2436.)| false
• Search Google Scholar
• Export Citation

80 Tsai, CM, Chang, KT, Wu, LH et al. 1996 Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines Cancer Res 56 206–209.

80 Tsai, CM, Chang, KT, Wu, LH et al. 1996Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell linesCancer Res56206–209.)| false
• Search Google Scholar
• Export Citation

81 Tutt, A, Ashworth, A 2008 Can genetic testing guide treatment in breast cancer Eur J Cancer 44 2774–2780.

81 Tutt, A, Ashworth, A2008Can genetic testing guide treatment in breast cancerEur J Cancer442774–2780.)| false
• Search Google Scholar
• Export Citation

82 Tutt, A, Wang, A, Rowland, C et al. 2008 Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature BMC Cancer 8 339.

82 Tutt, A, Wang, A, Rowland, C et al. 2008Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureBMC Cancer8339.)| false
• Search Google Scholar
• Export Citation

83 Ueda, T, Aozasa, K, Tsujimoto, M et al. 1989 Prognostic significance of Ki-67 reactivity in soft tissue sarcomas Cancer 63 1607–1611.

83 Ueda, T, Aozasa, K, Tsujimoto, M et al. 1989Prognostic significance of Ki-67 reactivity in soft tissue sarcomasCancer631607–1611.)| false
• Search Google Scholar
• Export Citation

84 Veer van ‘t, LJ, Dai, H, Vijver van de, MJ et al. 2003 Expression profiling predicts outcome in breast cancer Breast Cancer Res 5 57–58.

84 Veer van ‘t, LJ, Dai, H, Vijver van de, MJ et al. 2003Expression profiling predicts outcome in breast cancerBreast Cancer Res557–58.)| false
• Search Google Scholar
• Export Citation

85 Vijver van de, M, He, YD, Veer van ‘t, LJ et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999–2009.

85 Vijver van de, M, He, YD, Veer van ‘t, LJ et al. 2002A gene-expression signature as a predictor of survival in breast cancerN Engl J Med3471999–2009.)| false
• Search Google Scholar
• Export Citation

86 Weigelt, B, Hu, Z, He, X et al. 2005 Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res 65 9155–9158.

86 Weigelt, B, Hu, Z, He, X et al. 2005Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancerCancer Res659155–9158.)| false
• Search Google Scholar
• Export Citation

87 Wiechmann, L, Sampson, M, Stempel, M et al. 2009 Presenting features of breast cancer differ by molecular subtype Ann Surg Oncol 16 2705–2710.

87 Wiechmann, L, Sampson, M, Stempel, M et al. 2009Presenting features of breast cancer differ by molecular subtypeAnn Surg Oncol162705–2710.)| false
• Search Google Scholar
• Export Citation

88 Wiesner, FG, Magener, A, Fasching, PA et al. 2009 Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients Breast 18 135–141.

88 Wiesner, FG, Magener, A, Fasching, PA et al. 2009Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patientsBreast18135–141.)| false
• Search Google Scholar
• Export Citation